Compare 3-D Matrix Ltd. with Similar Stocks
Dashboard
1
With a growth in Net Sales of 88.84%, the company declared Outstanding results in Apr 26
- The company has declared positive results for the last 4 consecutive quarters
- ROCE(HY) Highest at 92.22%
- DEBT-EQUITY RATIO (HY) Lowest at -32.82 %
- OPERATING PROFIT MARGIN(Q) Highest at 17.75 %
2
With ROE of 24.57%, it has a very attractive valuation with a 8.42 Price to Book Value
3
Majority shareholders : FIIs
Stock DNA
Pharmaceuticals & Biotechnology
JPY 43,766 Million (Small Cap)
34.00
NA
0.00%
-0.29
24.57%
8.45
Revenue and Profits:
Net Sales:
3,540 Million
(Quarterly Results - Apr 2026)
Net Profit:
1,802 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.12%
0%
-31.12%
6 Months
-30.43%
0%
-30.43%
1 Year
44.26%
0%
44.26%
2 Years
177.17%
0%
177.17%
3 Years
130.07%
0%
130.07%
4 Years
16.17%
0%
16.17%
5 Years
13.18%
0%
13.18%
3-D Matrix Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
60.32%
EBIT Growth (5y)
15.58%
EBIT to Interest (avg)
-152.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
1.16
Tax Ratio
22.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
0.86%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
8.42
EV to EBIT
267.88
EV to EBITDA
267.88
EV to Capital Employed
11.52
EV to Sales
4.57
PEG Ratio
0.16
Dividend Yield
NA
ROCE (Latest)
4.30%
ROE (Latest)
24.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Apr 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.03%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Apr'26 - YoY
Apr'26
Apr'25
Change(%)
Net Sales
3,540.10
1,874.70
88.84%
Operating Profit (PBDIT) excl Other Income
628.40
-550.20
214.21%
Interest
2.90
14.80
-80.41%
Exceptional Items
218.10
6.50
3,255.38%
Consolidate Net Profit
1,801.50
-1,107.40
262.68%
Operating Profit Margin (Excl OI)
177.50%
-293.50%
47.10%
USD in Million.
Net Sales
YoY Growth in quarter ended Apr 2026 is 88.84% vs 16.85% in Apr 2025
Consolidated Net Profit
YoY Growth in quarter ended Apr 2026 is 262.68% vs -349.19% in Apr 2025
Annual Results Snapshot (Consolidated) - Apr'26
Apr'26
Apr'25
Change(%)
Net Sales
10,886.30
6,934.10
57.00%
Operating Profit (PBDIT) excl Other Income
1,335.80
-1,156.20
215.53%
Interest
18.00
74.40
-75.81%
Exceptional Items
180.50
4.60
3,823.91%
Consolidate Net Profit
4,155.90
-2,501.20
266.16%
Operating Profit Margin (Excl OI)
122.70%
-166.70%
28.94%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2026 is 57.00% vs 51.11% in Apr 2025
Consolidated Net Profit
YoY Growth in year ended Apr 2026 is 266.16% vs -878.94% in Apr 2025
About 3-D Matrix Ltd. 
3-D Matrix Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






